Navigation Links
Teva's 'Patient First' Initiative Highlights Struggle Against High Health Care Costs, Reminds Lawmakers of Reform Goals
Date:8/20/2009

Real Americans Share Experiences, Common Need for Patient-Centric Reform

WASHINGTON, Aug. 20 /PRNewswire-USNewswire/ -- Teva Pharmaceuticals USA, the world's leading generic pharmaceutical company, today announced the start of its "Patient First" project as part of the Year of Affordable Healthcare campaign. The initiative, available at: www.yearofaffordablehealth.com/patients, features a first-hand perspective of everyday Americans as they struggle with the enormous and sometimes insurmountable expense of paying for their prescription medicines.

The Patient First initiative features compelling, real-life stories like that of Rob Day, a father of two from Port Huron, Michigan. At age 19, Rob was diagnosed with Paroxysmal Nocturnal Hemoglobinuria (PNH), an extremely rare blood disorder. As his video and profile demonstrate, Rob has spent half his life waiting for a medicine to treat his rare condition. Now that he finally has it, he can't afford to keep it.

The medicine for his condition, a biologic, is extremely expensive, costing $389,000 a year. Rob knows that he must take this medicine for the rest of his life in order to stay alive but doesn't know how he and his family will continue to be able to afford his care.

An FDA approval pathway for generic biologic drugs that provides real, market-based competition, could yield more affordable versions of these biologic medicines for Rob and millions of other Americans in the years to come. In addition to greater access, the benefit of timely competition will be further incentives for innovative biologic medicines that treat diseases including diabetes, multiple sclerosis, Alzheimer's, Parkinson's, psoriasis and cancer. An approval pathway, like the one supported by the Obama Administration and many members of Congress, would do just that - provide relief to people like Rob while introducing billions of dollars in savings for our healthcare system.

"Rob's story is just one of a number of Patient First stories that chronicle the struggles of patients across America," said Debra Barrett, Senior Vice President of Teva Pharmaceuticals USA. "The common thread is the hope for meaningful health care reform that provides relief to those that need it most. Their stories should remind Congress and the White House of what this debate is all about."

To learn more about Rob's story, and other like his, visit the Patient First initiative on-line at: www.yearofaffordablehealth.com/patients

Teva's Year of Affordable Healthcare is a nationwide campaign to recognize the important role that generic drugs play in providing competitive and more affordable healthcare. In addition, the campaign calls upon federal legislators to enact further reforms, including passage of a competitive regulatory approval pathway for generic biologics to increase American access to affordable and lifesaving medicines.

Individuals and organizations can to lend their voices to the Patient First initiative by contacting the Year of Affordable Healthcare campaign at info@yearofaffordablehealth.com

About the Year of Affordable Healthcare

The Year of Affordable Healthcare campaign (www.yearofaffordablehealth.com) is a nationwide call for increased access to affordable healthcare for American citizens. The program coincides with the 25th anniversary of the landmark Hatch-Waxman Act, which created the modern generic pharmaceutical industry and has saved billions of healthcare dollars. For more information, additional videos and details on upcoming events, please visit the Year of Affordable Healthcare Campaign website at: www.yearofaffordablehealth.com.

About Teva

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the world's leading generic pharmaceutical company. The Company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80 percent of Teva's sales are in North America and Europe.

Media Contact: Denise Bradley

Phone: (215) 591-8974

E-mail: Denise.Bradley@tevausa.com


'/>"/>
SOURCE Teva Pharmaceuticals USA
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Newer Drug Beats Tamoxifen for Older Breast Cancer Patients
2. Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C
3. Tumor size and level of visceral pleura invasion can impact survival of NSCLC patients
4. Study shows carvedilol is effective in preventing variceal bleeding in cirrhotic patients
5. Laurence Barsh, DMD, Founder of Snoring Isn't Sexy, LLC Emphasizes Need to Evaluate and Treat Sleep Patients
6. Iterative reconstruction technique significantly reduces patient radiation dose during CT scans
7. Palliative care intervention for patients with advanced cancer provides quality of life benefits
8. Detroit Clinic Owner and Patient Recruiter Plead Guilty in $15 Million Fraud Scheme
9. Uninsured Patients to Receive Free Surgeries, Procedures
10. Free Compirion Bed Flow Webinar Helps Improve Patient Flow From ED to Inpatient Units
11. Identification Systems Group Pledges Support for Standardized Patient Health Identification Cards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a global ... announced that Premier Research, a leading clinical development service provider, has selected ERT’s ... increasingly complex, due in part to an array of circumstances including the use ...
(Date:2/23/2017)... ... (PRWEB) February 23, 2017 ... nation to come together to combine its favorite springtime pastime ... favorite fruit – apples! To celebrate National Nutrition Month, the ... “Apple Madness” bracket tournament – a five-week, five-round online competition ...
(Date:2/23/2017)... , ... February 23, 2017 , ... HealthPostures, the desk ... an expert sit stand solutions representative to the Minneapolis Home and Garden Show which ... the event that is garnering national attention is the Minneapolis Convention Center. , ...
(Date:2/22/2017)... York, NY (PRWEB) , ... February 22, 2017 ... ... professional life and athletics. It’s enough to overwork even the sharpest brain. , ... that offer peak healthy activity without over clocking the brain. Each capsule contains ...
(Date:2/22/2017)... ... February 22, 2017 , ... Secure Exchange Solutions, ... largest network of hospitals, health information exchanges, physicians and patients, announced today that ... (ONC-HIT) 2015 Edition Health IT Module Certification via Drummond Group LLC, an Authorized ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Research and Markets has announced the addition of the "Global ... 2025" report to their offering. ... The Global Cardiac Prosthetic Devices Market is ... next decade to reach approximately $8.9 billion by 2025. ... the given segments on global as well as regional levels presented ...
(Date:2/23/2017)... , Feb. 23, 2017  Spheryx, ... one poster presentation at PittCon 2017 Conference ... Pittcon is the world,s largest annual premier ... serves a wide array of industry, academic ... discovery and QA, food safety, environmental, bioterrorism ...
(Date:2/23/2017)... 23, 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT) ... oncology and dermatology biopharmaceutical company, today announced that it ... Rodrigues as special advisers to the Company,s Board ... the board on financial and corporate strategy. ... commitment of up to $2.5 million from Eric ...
Breaking Medicine Technology: